Who are Teriparatide (Forteo)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TERIPARATIDE, Teriparatide Pen Injector, FORSTEO, Teriparatide (rDNA origin), Teriparatide (PF708).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teriparatide-forteo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Teriparatide (Forteo) — Competitive Intelligence Brief

Teriparatide (Forteo) (Teriparatide (Forteo)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parathyroid hormone analog. Area: Endocrinology / Bone Metabolism.

marketed Parathyroid hormone analog PTH1 receptor (parathyroid hormone 1 receptor) Endocrinology / Bone Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Teriparatide (Forteo) (Teriparatide (Forteo)) — M.D. Anderson Cancer Center. Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Teriparatide (Forteo) TARGET	Teriparatide (Forteo)	M.D. Anderson Cancer Center	marketed	Parathyroid hormone analog	PTH1 receptor (parathyroid hormone 1 receptor)
TERIPARATIDE	TERIPARATIDE		marketed	Parathyroid Hormone Analog [EPC]		2002-01-01
Teriparatide Pen Injector	Teriparatide Pen Injector	University of Edinburgh	marketed	Parathyroid hormone analog	PTH1 receptor
FORSTEO	FORSTEO	Shenzhen Salubris Pharmaceuticals Co., Ltd.	marketed	Parathyroid hormone analog	PTH1 receptor
Teriparatide (rDNA origin)	Teriparatide (rDNA origin)	Bio Sidus SA	marketed	Parathyroid hormone analog	PTH1 receptor (PTHR1)
Teriparatide (PF708)	Teriparatide (PF708)	Pfenex, Inc	phase 3	Parathyroid hormone analog	PTH1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parathyroid hormone analog class)

Bio Sidus SA · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Pfenex, Inc · 1 drug in this class
Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teriparatide (Forteo) — Competitive Intelligence Brief. https://druglandscape.com/ci/teriparatide-forteo. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab